Novartis announced data from a Phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced...
On 27 June 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...
The FDA has approved Tafinlar (dabrafenib), from Glaxo Smith Kline, as a single-agent oral treatment for unresectable Melanoma or Metastatic...
The FDA has approved Mekinist (trametinib) for use in combination with Tafinlar (dabrafenib), both from Glaxo Smith Kline, for the...
A Phase III study (COMBI-d) of the combination of Tafinlar (dabrafenib) and Mekinist (trametinib), from Glaxo Smith Kline, versus therapy...
The National Institute for Health and Care Excellence (NICE) has recommended the use of Tafinlar (dabrafenib) from GSK for the...
The FDA has granted Priority Review designation to a supplemental New Drug Applications (sNDAs) from GSK for combined use of...
The European Commission has granted marketing authorisation for Tafinlar (dabrafenib), from Glaxo Smith Kline, as an oral targeted treatment indicated...
Novartis announced a new data analysis of COMBI-AD, a phase III multi-center study evaluating Tafinlar (dabrafenib) in combination with Mekinist...
Novartis announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive...